Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
88 studies match
| PfizerINDUSTRY |
| 5 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 132 | PfizerINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | recruiting | Phase 1 | 250 | PfizerINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT05379595 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer(OrigAMI-1) | recruiting | Phase 1 / Phase 2 | 225 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT07227298 | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | recruiting | Phase 1 / Phase 2 | 162 | PfizerINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT06447662 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | active not recruiting | Phase 1 | 64 | PfizerINDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05471843 | Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 125 | BeOne MedicinesINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation(AUGMENT-101) | recruiting | Phase 1 / Phase 2 | 447 | Syndax PharmaceuticalsINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT02772003 | DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | active not recruiting | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2026 | clinicaltrials |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | recruiting | Phase 1 | 398 | Astellas Pharma Global Development, Inc.INDUSTRY | 8 | Sep 11, 2026 | clinicaltrials |
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 74 | PfizerINDUSTRY | 9 | Sep 9, 2026 | clinicaltrials |
| NCT06624085 | A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 50 | Hoffmann-La RocheINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT06075810 | A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | recruiting | Phase 1 | 48 | MBQ PharmaINDUSTRY | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05150691 | A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 796 | DualityBio Inc.INDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | terminated | Phase 1 | 226 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 14, 2026 | clinicaltrials |
| NCT03504644 | Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 7, 2026 | clinicaltrials |
| NCT03997370 | Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | active not recruiting | Phase 1 | 350 | NRG OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 681 | Astellas Pharma IncINDUSTRY | 7 | Jul 31, 2026 | clinicaltrials |
| NCT03785249 | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | active not recruiting | Phase 1 / Phase 2 | 731 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05609370 | A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 4 | Jul 23, 2026 | clinicaltrials |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 | 291 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2026 | clinicaltrials |
| NCT05874414 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 98 | GenfitINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT04077463 | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer(Chrysalis-2) | active not recruiting | Phase 1 | 701 | Janssen Research & Development, LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | recruiting | Phase 1 / Phase 2 | 258 | SanofiINDUSTRY | 10 | Jun 16, 2026 | clinicaltrials |
| NCT05438329 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 1,123 | DualityBio Inc.INDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
| NCT05595460 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | active not recruiting | Phase 1 | 21 | RayzeBio, Inc.INDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors(iintune-1) | completed | Phase 1 / Phase 2 | 248 | TakedaINDUSTRY | 11 | Apr 8, 2026 | clinicaltrials |
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | active not recruiting | Phase 1 / Phase 2 | 48 | Servier Bio-Innovation LLCINDUSTRY | 15 | Apr 3, 2026 | clinicaltrials |
| NCT03288545 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer(EV-103) | terminated | Phase 1 / Phase 2 | 348 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Mar 24, 2026 | clinicaltrials |
| NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | active not recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | active not recruiting | Phase 1 / Phase 2 | 71 | PfizerINDUSTRY | 8 | Feb 27, 2026 | clinicaltrials |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 334 | TakedaINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | terminated | Phase 1 | 64 | Mirati Therapeutics Inc.INDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | completed | Phase 1 | 168 | AbbVieINDUSTRY | 10 | Dec 10, 2025 | clinicaltrials |
Data updated 15 hours agoSource updated unknownsource: clinicaltrials